Effects of alendronate and alfacalcidol on bone in patients with myasthenia gravis initiating glucocorticoids treatment

Fang Lv(Liaoning Normal University), Mei Li(Yantaishan Hospital), Weibo Xia(Chinese Academy of Medical Sciences & Peking Union Medical College), Lujiao Li(Chinese Academy of Medical Sciences & Peking Union Medical College), Yan Jiang(Chinese Academy of Medical Sciences & Peking Union Medical College), Xiaoping Xing(Chinese Academy of Medical Sciences & Peking Union Medical College), Yuwen Song(Chinese Academy of Medical Sciences & Peking Union Medical College), Ou Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Xiaojie Xu(Dalian Medical University), Yuzhou Guan(Chinese Academy of Medical Sciences & Peking Union Medical College), Doudou Ma(Chinese Academy of Medical Sciences & Peking Union Medical College)
Clinical Endocrinology
December 20, 2017
10.1111/cen.13537
Cited by 7

Related Papers

Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC
|Journal of Thoracic Oncology|2020|415
Luteolin-loaded solid lipid nanoparticles synthesis, characterization, & improvement of bioavailability, pharmacokinetics in vitro and vivo studies
|Journal of Nanoparticle Research|2014|128
CircCEMIP promotes anoikis-resistance by enhancing protective autophagy in prostate cancer cells
|Journal of Experimental & Clinical Cancer Research|2022|115
Denosumab or romosozumab therapy and risk of cardiovascular events in patients with primary osteoporosis: Systematic review and meta- analysis
|Bone|2019|110
The influence of different growth hormone addition protocols to poor ovarian responders on clinical outcomes in controlled ovary stimulation cycles
|Medicine|2017|100